S3 guideline: Diagnosis and treatment of epidermal necrolysis (Stevens-Johnson syndrome and toxic epidermal necrolysis) - Part 1: Diagnosis, initial management, and immunomodulating systemic therapy.
Drug reaction
Lyell syndrome
Stevens‐Johnson syndrome
epidermal necrolysis
toxic epidermal necrolysis
Journal
Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
ISSN: 1610-0387
Titre abrégé: J Dtsch Dermatol Ges
Pays: Germany
ID NLM: 101164708
Informations de publication
Date de publication:
23 Sep 2024
23 Sep 2024
Historique:
received:
12
06
2024
accepted:
18
06
2024
medline:
24
9
2024
pubmed:
24
9
2024
entrez:
24
9
2024
Statut:
aheadofprint
Résumé
Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS/TEN) are rare, predominantly drug-induced, acute, life-threatening diseases of skin and mucosae. SJS and TEN are nowadays considered variants of one disease entity with varying degrees of severity called epidermal necrolysis (EN). EN is associated with high morbidity and mortality and constitutes a major disease burden for affected patients. The guideline "Diagnosis and treatment of epidermal necrolysis (Stevens-Johnson syndrome and toxic epidermal necrolysis)" was developed under systematic consideration of existing scientific literature and in a formal consensus process according to regulations issued by the Association of Scientific Medical Societies in Germany (AWMF) to establish an evidence-based framework to support clinical decision-making. The interdisciplinary guideline commission consisted of representatives from various specialist societies and patient representatives. The guideline is aimed at specialists in the fields of dermatology, ophthalmology, plastic surgery, intensive care, and pediatrics in hospitals and offices, as well as other medical speciallved in the diagnosis and treatment of EN. The guideline is also aimed at patients, their relatives, insurance funds, and policymakers. This first part focuses on the diagnostic aspects, the initial management as well as the immunomodulating systemic therapy.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 The Author(s). Journal der Deutschen Dermatologischen Gesellschaft published by John Wiley & Sons Ltd on behalf of Deutsche Dermatologische Gesellschaft.
Références
Kaminski‐Hartenthaler A, Meerpohl JJ, Gartlehner G, et al. [GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations]. Z Evid Fortbild Qual Gesundhwes. 2014;108:413‐420.
Lyell A. Toxic epidermal necrolysis (the scalded skin syndrome): a reappraisal. Br J Dermatol. 1979;100:69‐86.
Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med. 1994;331:1272‐1285.
Bastuji‐Garin S, Rzany B, Stern RS, et al. Clinical classification of cases of toxic epidermal necrolysis, Stevens‐Johnson syndrome, and erythema multiforme. Arch Dermatol. 1993;129:92‐96.
Auquier‐Dunant A, Mockenhaupt M, Naldi L, et al. Correlations between clinical patterns and causes of erythema multiforme majus, Stevens‐Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study. Arch Dermatol. 2002;138:1019‐1024.
Grünwald P, Mockenhaupt M, Panzer R, Emmert S. Erythema exsudativum multiforme, Stevens‐Johnson‐Syndrom/toxische epidermale Nekrolyse – Diagnostik und Therapie. J Dtsch Dermatol Ges. 2020;18:547‐553.
Schwartz RA, McDonough PH, Lee BW. Toxic epidermal necrolysis: Part I. Introduction, history, classification, clinical features, systemic manifestations, etiology, and immunopathogenesis. J Am Acad Dermatol. 2013;69:173. e1‐13;quiz185‐186.
Mockenhaupt M, Roujeau J‐C. Epidermal Necrolysis (Stevens‐Johnson Syndrome and Toxic Epidermal Necrolysis). In: Kang S, Amagai M, Bruckner AL, et al. (eds.) Fitzpatrick's Dermatology, 9e. McGraw‐Hill Education; 2019.
Roujeau JC. The spectrum of Stevens‐Johnson syndrome and toxic epidermal necrolysis: a clinical classification. J Invest Dermatol. 1994;102:28S‐30S.
Salopek TG. Nikolsky's sign: is it 'dry' or is it 'wet'? Br J Dermatol. 1997;136:762‐767.
Paulmann M, Mockenhaupt M. Schwere arzneimittelinduzierte Hautreaktionen: Klinik, Diagnostik, Ätiologie und Therapie. J Dtsch Dermatol Ges. 2015;13:625‐645.
Mockenhaupt M. Severe cutaneous adverse drug reactions. In: Burgdorf WHC PG, Wolff HH, Landthaler M (eds.). Braun‐Falco's Dermatology. Heidelberg: Springer; 2009.
Sidoroff A, Halevy S, Bavinck JN, et al. Acute generalized exanthematous pustulosis (AGEP) – a clinical reaction pattern. J Cutan Pathol. 2001;28:113‐119.
Mockenhaupt M, Idzko M, Grosber M, et al. Epidemiology of staphylococcal scalded skin syndrome in Germany. J Invest Dermatol. 2005;124:700‐703.
Ziemer M, Mockenhaupt M. Severe Drug‐Induced Skin Reactions: Clinical Pattern, Diagnostics and Therapy. In: Uday K, ed. Skin Biopsy. IntechOpen; 2011:Ch. 6.
Maverakis E, Wang EA, Shinkai K, et al. Stevens‐Johnson Syndrome and Toxic Epidermal Necrolysis Standard Reporting and Evaluation Guidelines: Results of a National Institutes of Health Working Group. JAMA Dermatol. 2017;153:587‐592.
Creamer D, Walsh SA, Dziewulski P, et al. U.K. guidelines for the management of Stevens‐Johnson syndrome/toxic epidermal necrolysis in adults 2016. Br J Dermatol. 2016;174:1194‐1227.
Levi N, Bastuji‐Garin S, Mockenhaupt M, et al. Medications as risk factors of stevens‐johnson syndrome and toxic epidermal necrolysis in children: A pooled analysis. Pediatrics. 2009;123(2):e297‐e304.
Krüger D, Paulmann M, Mockenhaupt M. Stevens‐Johnson‐Syndrom/Toxisch epidermale Nekrolyse im Kindes‐ und Jugendalter: Häufigkeit, Ausprägung und Auslöser. J Dtsch Dermatol Ges. 2019;17:69‐70.
Guillaume JC, Roujeau JC, Revuz J, et al. The culprit drugs in 87 cases of toxic epidermal necrolysis (Lyell's syndrome). Arch Dermatol. 1987;123:1166‐1170.
Correia O, Chosidow O, Saiag P, et al. Evolving Pattern of Drug‐Induced Toxic Epidermal Necrolysis. Dermatology (Basel, Switzerland). 1993;186:32‐37.
Roujeau JC, Guillaume JC, Fabre JP, et al. Toxic epidermal necrolysis (Lyell syndrome). Incidence and drug etiology in France, 1981–1985. Arch Dermatol. 1990;126:37‐42.
Schöpf E, Stühmer A, Rzany B, et al. Toxic epidermal necrolysis and Stevens‐Johnson syndrome. An epidemiologic study from West Germany. Arch Dermatol. 1991;127:839‐842.
Kubo H, Irie A, Inagaki F, Hoshi M. Melibiosylceramide as the sole ceramide dihexoside from the eggs of the sea urchin, Anthocidaris crassispina. J Biochem. 1988;104:755‐760.
Mockenhaupt M, Viboud C, Dunant A, et al. Stevens‐Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR‐study. J Invest Dermatol. 2008;128:35‐44.
Yetiv JZ, Bianchine JR, Owen JA, Jr. Etiologic factors of the Stevens‐Johnson syndrome. South Med J. 1980;73:599‐602.
Seminario‐Vidal L, Kroshinsky D, Malachowski SJ, et al. Society of Dermatology Hospitalists supportive care guidelines for the management of Stevens‐Johnson syndrome/toxic epidermal necrolysis in adults. J Am Acad Dermatol. 2020;82:1553‐1567.
Sassolas B, Haddad C, Mockenhaupt M, et al. ALDEN, an algorithm for assessment of drug causality in Stevens‐Johnson Syndrome and toxic epidermal necrolysis: comparison with case‐control analysis. Clin Pharmacol Ther. 2010;88:60‐68.
Millar BC, Bell JB, Montes A, et al. Colony stimulating activity in the serum of patients with multiple myeloma is enhanced by interleukin 3: a possible role for interleukin 3 after high dose melphalan and autologous bone marrow transplantation for multiple myeloma. Br J Haematol. 1990;75:366‐372.
Liew YCC, Choo KJL, Oh CC, et al. Mycoplasma‐induced Stevens‐Johnson syndrome/toxic epidermal necrolysis: Case‐control analysis of a cohort managed in a specialized center. J Am Acad Dermatol. 2022;86:811‐817.
Naegele D, Sekula P, Paulmann M, Mockenhaupt M. Incidence of Epidermal Necrolysis: Results of the German Registry. J Invest Dermatol. 2020;140:2525‐2527.
Bastuji‐Garin S, Fouchard N, Bertocchi M, et al. SCORTEN: A Severity‐of‐Illness Score for Toxic Epidermal Necrolysis. J Invest Dermatol. 2000;115:149‐153.
Bansal S, Garg VK, Sardana K, Sarkar R. A clinicotherapeutic analysis of Stevens‐Johnson syndrome and toxic epidermal necrolysis with an emphasis on the predictive value and accuracy of SCORe of Toxic Epidermal Necrolysis. Int J Dermatol. 2015;54:e18‐e26.
Guegan S, Bastuji‐Garin S, Poszepczynska‐Guigne E, et al. Performance of the SCORTEN during the first five days of hospitalization to predict the prognosis of epidermal necrolysis. J Invest Dermatol. 2006;126:272‐276.
Sekula P, Dunant A, Mockenhaupt M, et al. Comprehensive survival analysis of a cohort of patients with Stevens‐Johnson syndrome and toxic epidermal necrolysis. J Invest Dermatol. 2013;133:1197‐1204.
Torres‐Navarro I, Briz‐Redon A, Botella‐Casas G, et al. Accuracy of SCORTEN and ABCD‐10 to predict mortality and the influence of renal function in Stevens‐Johnson syndrome/toxic epidermal necrolysis. J Dermatol. 2020;47:1182‐1186.
von Wild T, Stollwerck PL, Namdar T, et al. Are Multimorbidities Underestimated in Scoring Systems of Stevens‐Johnson Syndrome and Toxic Epidermal Necrolysis Like in SCORTEN? Eplasty. 2012;12:e35‐NA.
Chronopoulos A, Mockenhaupt M, Pleyer U. Okuläre Beteiligung bei Stevens‐Johnson‐Syndrom und toxisch epidermaler Nekrolyse. Der Ophthalmologe. 2021;118:519‐532.
Chang YS, Huang FC, Tseng SH, et al. Erythema multiforme, Stevens‐Johnson syndrome, and toxic epidermal necrolysis: acute ocular manifestations, causes, and management. Cornea. 2007;26:123‐129.
Deutsche Gesellschaft für Anästhesiologie und Intensivmedizin (DGAI), Deutsche Interdisziplinäre Vereinigung für Intensiv‐ und Notfallmedizin (DIVI). S3‐Leitlinie Analgesie, Sedierung und Delirmanagement in der Intensivmedizin (DAS‐Leitlinie), Version 5.0. 2021;AWMF‐Registernummer: 001/012.
Bachot N, Roujeau JC. Physiopathology and treatment of severe drug eruptions. Curr Opin Allergy Clin Immunol. 2001;1:293‐298.
Deutsche Gesellschaft für Allgemeinmedizin und Familienmedizin e.V. (DEGAM). S3‐Leitlinie Multimorbidität – Living guideline, Version 2.1. 2023;AWMF‐Register‐Nr. 053‐047LG.
Brand R, Rohr JB. Toxic epidermal necrolysis in Western Australia. Australas J Dermatol. 2000;41:31‐33.
Chatproedprai S, Wutticharoenwong V, Tempark T, Wananukul S. Clinical Features and Treatment Outcomes among Children with Stevens‐Johnson Syndrome and Toxic Epidermal Necrolysis: A 20‐Year Study in a Tertiary Referral Hospital. Dermatol Res Pract. 2018;2018:3061084.
Dicle Ö, Yılmaz E, Alpsoy E. Stevens‐Johnson Syndrome and Toxic Epidermal Necrolysis: A Retrospective Evaluation. [Turkish]. Turkderm‐Turk Arch Dermatol Venereol. 2009;43:15‐20.
Kim KJ, Lee DP, Suh HS, et al. Toxic epidermal necrolysis: analysis of clinical course and SCORTEN‐based comparison of mortality rate and treatment modalities in Korean patients. Acta Derm Venereol. 2005;85:497‐502.
Koh MJ, Tay YK. Stevens‐Johnson syndrome and toxic epidermal necrolysis in Asian children. J Am Acad Dermatol. 2010;62:54‐60.
Léauté‐Labrèze C, Lamireau T, Chawki D, et al. Diagnosis, classification, and management of erythema multiforme and Stevens‐Johnson syndrome. Arch Dis Child. 2000;83:347‐352.
Shah R, Chen ST, Kroshinsky D. Use of cyclosporine for the treatment of Stevens‐Johnson syndrome/toxic epidermal necrolysis. J Am Acad Dermatol. 2021;85:512‐513.
Singh GK, Chatterjee M, Verma R. Cyclosporine in Stevens Johnson syndrome and toxic epidermal necrolysis and retrospective comparison with systemic corticosteroid. Indian J Dermatol Venereol Leprol. 2013;79:686‐692.
Thakur V, Vinay K, Kumar S, et al. Factors Predicting the Outcome of Stevens‐Johnson Syndrome and Toxic Epidermal Necrolysis: A 5‐Year Retrospective Study. Indian Dermatol Online J. 2021;12:258‐265.
Wang CW, Yang LY, Chen CB, et al. Randomized, controlled trial of TNF‐alpha antagonist in CTL‐mediated severe cutaneous adverse reactions. J Clin Invest. 2018;128:985‐996.
Yip LW, Thong BY, Tan AW, et al. High‐dose intravenous immunoglobulin in the treatment of toxic epidermal necrolysis: a study of ocular benefits. Eye. 2005;19:846‐853.
Zimmermann S, Sekula P, Venhoff M, et al. Systemic Immunomodulating Therapies for Stevens‐Johnson Syndrome and Toxic Epidermal Necrolysis: A Systematic Review and Meta‐analysis. JAMA Dermatol. 2017;153:514‐522.
Jacobsen A, Olabi B, Langley A, et al. Systemic interventions for treatment of Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome. Cochrane Database Syst Rev. 2022;3:Cd013130.
Brown KM, Silver GM, Halerz M, et al. Toxic epidermal necrolysis: does immunoglobulin make a difference? J Burn Care Rehabil. 2004;25:81‐88.
Chan L, Cook DK. A 10‐year retrospective cohort study of the management of toxic epidermal necrolysis and Stevens‐Johnson syndrome in a New South Wales state referral hospital from 2006 to 2016. Int J Dermatol. 2019;58:1141‐1147.
Dreyer SD, Torres J, Stoddard M, et al. Efficacy of Etanercept in the Treatment of Stevens‐Johnson Syndrome and Toxic Epidermal Necrolysis. Cutis. 2021;107:E22‐E28.
González‐Herrada C, Rodríguez‐Martín S, Cachafeiro L, et al. Cyclosporine Use in Epidermal Necrolysis Is Associated with an Important Mortality Reduction: Evidence from Three Different Approaches. J Invest Dermatol. 2017;137:2092‐2100.
Gravante G, Delogu D, Marianetti M, et al. Toxic epidermal necrolysis and Steven Johnson syndrome: 11‐years experience and outcome. Eur Rev Med Pharmacol Sci. 2007;11:119‐127.
Imahara SD, Holmes 4th JH, Heimbach DM, et al. SCORTEN overestimates mortality in the setting of a standardized treatment protocol. J Burn Care Res. 2006;27:270‐275.
Kirchhof MG, Miliszewski MA, Sikora S, et al. Retrospective review of Stevens‐Johnson syndrome/toxic epidermal necrolysis treatment comparing intravenous immunoglobulin with cyclosporine. J Am Acad Dermatol. 2014;71:941‐947.
Marchitto MC, Sung S, Doong J, Chien AL. Toxic epidermal necrolysis: a review of 20 years of data. J Eur Acad Dermatol Venereol. 2018;32:e263‐e264.
Paquet P, Kaveri S, Jacob E, et al. Skin immunoglobulin deposition following intravenous immunoglobulin therapy in toxic epidermal necrolysis. Exp Dermatol. 2006;15:381‐386.
Schneck J, Fagot JP, Sekula P, et al. Effects of treatments on the mortality of Stevens‐Johnson syndrome and toxic epidermal necrolysis: A retrospective study on patients included in the prospective EuroSCAR Study. J Am Acad Dermatol. 2008;58:33‐40.
Shortt R, Gomez M, Mittman N, Cartotto R. Intravenous immunoglobulin does not improve outcome in toxic epidermal necrolysis. J Burn Care Rehabil. 2004;25:246‐255.
Williams V, Reddy M, Bansal A, et al. Intensive care needs and long‐term outcome of pediatric toxic epidermal necrolysis ‐ A 10‐year experience. Int J Dermatol. 2021;60:44‐52.
Bachot N, Revuz J, Roujeau JC. Intravenous immunoglobulin treatment for Stevens‐Johnson syndrome and toxic epidermal necrolysis: a prospective noncomparative study showing no benefit on mortality or progression. Arch Dermatol. 2003;139:33‐36.
Poizeau F, Gaudin O, Le Cleach L, et al. Cyclosporine for Epidermal Necrolysis: Absence of Beneficial Effect in a Retrospective Cohort of 174 Patients‐Exposed/Unexposed and Propensity Score‐Matched Analyses. J Invest Dermatol. 2018;138:1293‐1300.
Wolkenstein P, Latarjet J, Roujeau JC, et al. Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis. Lancet. 1998;352:1586‐1589.
Hsieh MH, Watanabe T, Aihara M. Recent Dermatological Treatments for Stevens‐Johnson Syndrome and Toxic Epidermal Necrolysis in Japan. Front Med (Lausanne). 2021;8:636924.
Jagadeesan S, Sobhanakumari K, Sadanandan S, et al. Low dose intravenous immunoglobulins and steroids in toxic epidermal necrolysis: A prospective comparative open‐labelled study of 36 cases. Indian J Dermatol Venereol Leprol. 2013;79:506‐511.
Xiao Y, Gang W. Clinical analysis of severe drug eruption treated with hemoperfusion and continuous renal replacement therapy combined. Journal of the Dermatology Nurses' Association Conference: 24th World Congress of Dermatology Milan Italy. 2019;12.
Yang Y, Xu J, Li F, Zhu X. Combination therapy of intravenous immunoglobulin and corticosteroid in the treatment of toxic epidermal necrolysis and Stevens‐Johnson syndrome: a retrospective comparative study in China. Int J Dermatol. 2009;48:1122‐1128.
Yang L, Shou YH, Li F, et al. Intravenous Immunoglobulin Combined With Corticosteroids for the Treatment of Stevens‐Johnson Syndrome/Toxic Epidermal Necrolysis: A Propensity‐Matched Retrospective Study in China. Front Pharmacol. 2022;12:750173.
Yeong EK, Lee CH, Hu FC, M ZW. Serum bicarbonate as a marker to predict mortality in toxic epidermal necrolysis. J Intensive Care Med. 2011;26:250‐254.
Yun SJ, Choi MS, Piao MS, et al. Serum lactate dehydrogenase is a novel marker for the evaluation of disease severity in the early stage of toxic epidermal necrolysis. Dermatology. 2008;217:254‐259.
Zhang J, Lu CW, Chen CB, et al. Evaluation of Combination Therapy With Etanercept and Systemic Corticosteroids for Stevens‐Johnson Syndrome and Toxic Epidermal Necrolysis: A Multicenter Observational Study. J Allergy Clin Immunol Pract. 2022;10:1295‐1304. e6.
Zhu QY, Ma L, Luo XQ, Huang HY. Toxic epidermal necrolysis: performance of SCORTEN and the score‐based comparison of the efficacy of corticosteroid therapy and intravenous immunoglobulin combined therapy in China. J Burn Care Res. 2012;33:e295‐308.
Ao S, Gao X, Zhan J, et al. Inhibition of tumor necrosis factor improves conventional steroid therapy for Stevens‐Johnson syndrome/toxic epidermal necrolysis in a cohort of patients. J Am Acad Dermatol. 2022;86:1236‐1245.
Sullivan JR, Watson A. Lamotrigine‐induced toxic epidermal necrolysis treated with intravenous cyclosporin: a discussion of pathogenesis and immunosuppressive management. Australas J Dermatol. 1996;37:208‐212.